share_log

Around $10M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying

Around $10M Bet On This Biotechnology Stock? Check Out These 3 Stocks Insiders Are Buying

在这只生物技术股票上押注大约1000万美元?看看内部人士正在买入的这三只股票
Benzinga Real-time News ·  2023/01/19 07:17

Although US stocks closed lower on Wednesday, there were a few notable insider trades.

尽管周三美国股市收低,但仍有一些值得注意的内幕交易。

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

当内部人士购买股票时,这表明他们对公司前景充满信心,或者他们认为股票很划算。无论哪种方式,这都预示着做多该股的机会。不应将内幕购买视为做出投资或交易决策的唯一指标。充其量,它可以为购买决定提供信心。

Below is a look at a few recent notable insider purchases. For more, check out Benzinga's insider transactions platform.

以下是最近一些值得注意的内幕收购。欲了解更多,请查看 本辛加的内幕交易 平台。

Lifecore Biomedical

生命科生物医学

  • The Trade: Lifecore Biomedical, Inc. (NASDAQ:LFCR) 10% owner Joshua Landes acquired a total of 627,746 shares an average price of $7.97. To acquire these shares, it cost around $5 million.
  • What's Happening: Lifecore Biomedical recently received notice from Nasdaq regarding delayed quarterly report.
  • What Lifecore Biomedical Does: Lifecore Biomedical, incorporated in 1986, operates as an integrated contract development and manufacturing organization in the United States and internationally..
  • 交易: Lifecore 生物医学有限公司 (纳斯达克股票代码:LFCR)10% 的所有者约书亚·兰德斯 共收购了 627,746 股股票 平均价格为7.97美元。收购这些股票的费用约为500万美元。
  • 发生了什么: Lifecore Biomedical最近收到了纳斯达克关于延迟季度报告的通知。
  • Lifecore 生物医学是做什么的: Lifecore Biomedical 成立于 1986 年,是一家综合合同开发和制造组织,在美国和国际上运营。

Zymeworks

Zymework

  • The Trade: Zymeworks Inc. (NASDAQ:ZYME) 10% owner Ecor Capital LLC acquired a total of 985,100 shares at an average price of $9.84. To acquire these shares, it cost around $9.7 million.
  • What's Happening: Zymeworks recently issued corporate update on key strategic priorities and outlook for 2023.
  • What Zymeworks Does: Zymeworks BC Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics.
  • 交易: Zymeworks Inc. 纳斯达克股票代码:ZYME)10% 所有者 Ecor Capital LLC 共收购了985,100股股票 平均价格为9.84美元。收购这些股票的成本约为970万美元。
  • 发生了什么: Zymeworks最近发布了关于2023年关键战略优先事项和展望的公司最新消息。
  • Zymeworks 的作用: Zymeworks BC Inc是一家临床阶段的生物制药公司,致力于下一代多功能生物疗法的发现、开发和商业化。

Don't forget to check out our premarket coverage here

别忘了在这里查看我们的上市前报道

Neogen

Neoge

  • The Trade: Neogen Corporation (NASDAQ:NEOG) Chief Operating Officer Edward Douglas Jones bought a total of 2,500 shares at an average price of $17.91. To acquire these shares, it cost around $44.77 thousand.
  • What's Happening: Neogen recently reported better-than-expected Q2 results.
  • What Neogen Does: Neogen Corporation, headquartered in Lansing, Michigan, develops, manufactures, and markets various products for food and animal safety.
  • 交易: Neogen 公司 (纳斯达克股票代码:NEOG)首席运营官爱德华道格拉斯·琼斯 共购买了 2,500 股股票 平均价格为17.91美元。收购这些股票的成本约为44.77万美元。
  • 发生了什么: Neogen最近公布的第二季度业绩好于预期。
  • Neogen 的作用: 总部位于密歇根州兰辛的Neogen Corporation开发、制造和销售各种食品和动物安全产品。

Check This Out: Investor Optimism Declines As Nasdaq Snaps 7-Day Win Streak

看看这个: 随着纳斯达克连续7天上涨,投资者的乐观情绪下降

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发